Medical specialists from Canada tagged as investigators in clinical trials studying Melanoma

Total 37 results

Arif Awan
Seen in:
- Ontario, Ottawa, Ottawa Hospital Cancer Centre
- Ontario, Ottawa, University of Ottawa / Ottawa General Hospital
Trials:
- NCT05571839 (Principal Investigator)
- NCT04609566 (Principal Investigator)
- NCT05194072 (Principal Investigator)
- NCT04665921 (Principal Investigator)
- NCT05229900 (Principal Investigator)
Conditions:
Ashley Chopek
Seen in:
- Manitoba, Winnipeg, CancerCare Manitoba
Trials:
- NCT04759586 (Principal Investigator)
- NCT05457556 (Principal Investigator)
- NCT03794349 (Principal Investigator)
- NCT03067181 (Principal Investigator)
- NCT05099003 (Principal Investigator)
- NCT03914625 (Principal Investigator)
- NCT03007147 (Principal Investigator)
- NCT02402244 (Principal Investigator)
- NCT05304585 (Principal Investigator)
- NCT04684368 (Principal Investigator)
- NCT04322318 (Principal Investigator)
- NCT03817398 (Principal Investigator)
- NCT04726241 (Principal Investigator)
- NCT05675410 (Principal Investigator)
- NCT04994132 (Principal Investigator)
- NCT03959085 (Principal Investigator)
- NCT03223753 (Principal Investigator)
Conditions:
Bertrand Routy, MD, PhD
Seen in:
- Quebec, Montréal, Centre Hospitalier de l'Universite de Montreal (CHUM)
Trials:
- NCT05303493 (Principal Investigator)
- NCT04951583 (Principal Investigator)
- NCT05805319 (Principal Investigator)
Conditions:
Bruno Michon
Seen in:
- Quebec, CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
- Quebec, Centre Hospitalier Universitaire de Quebec
Trials:
- NCT04759586 (Principal Investigator)
- NCT04576117 (Principal Investigator)
- NCT04166409 (Principal Investigator)
- NCT01790152 (Principal Investigator)
- NCT03794349 (Principal Investigator)
- NCT03533582 (Principal Investigator)
- NCT03067181 (Principal Investigator)
- NCT05099003 (Principal Investigator)
- NCT03914625 (Principal Investigator)
- NCT03007147 (Principal Investigator)
- NCT02402244 (Principal Investigator)
- NCT05304585 (Principal Investigator)
- NCT04684368 (Principal Investigator)
- NCT04322318 (Principal Investigator)
- NCT03817398 (Principal Investigator)
- NCT04726241 (Principal Investigator)
- NCT04293562 (Principal Investigator)
- NCT05675410 (Principal Investigator)
- NCT02176967 (Principal Investigator)
- NCT00904241 (Principal Investigator)
- NCT04994132 (Principal Investigator)
- NCT03959085 (Principal Investigator)
Conditions:
Catalin Mihalcioiu, MD
Seen in:
- Quebec, Montréal, McGill University Health Center
Trials:
- NCT04951583 (Principal Investigator)
Conditions:
- Non Small Cell Lung Cancer Metastatic;
- Advanced Melanoma
Christopher Baliski
Seen in:
- British Columbia, Kelowna, BCCA - Cancer Centre for the Southern Interior
Trials:
- NCT03860883 (Principal Investigator)
Conditions:
- Cutaneous Melanoma, Stage II
Craig Erker
Seen in:
- Nova Scotia, Halifax, IWK Health Centre
Trials:
- NCT04759586 (Principal Investigator)
- NCT04576117 (Principal Investigator)
- NCT02724579 (Principal Investigator)
- NCT03871257 (Principal Investigator)
- NCT04166409 (Principal Investigator)
- NCT03794349 (Principal Investigator)
- NCT03533582 (Principal Investigator)
- NCT03067181 (Principal Investigator)
- NCT05099003 (Principal Investigator)
- NCT03914625 (Principal Investigator)
- NCT03007147 (Principal Investigator)
- NCT02402244 (Principal Investigator)
- NCT03126916 (Principal Investigator)
- NCT05304585 (Principal Investigator)
- NCT05235165 (Principal Investigator)
- NCT04322318 (Principal Investigator)
- NCT03817398 (Principal Investigator)
- NCT04726241 (Principal Investigator)
- NCT04293562 (Principal Investigator)
- NCT00898365 (Principal Investigator)
- NCT05675410 (Principal Investigator)
- NCT02176967 (Principal Investigator)
- NCT05602194 (Principal Investigator)
- NCT04994132 (Principal Investigator)
- NCT03959085 (Principal Investigator)
- NCT04089358 (Principal Investigator)
Conditions:
David B. Dix
Seen in:
- British Columbia, Vancouver, British Columbia Children's Hospital
Trials:
- NCT02724579 (Principal Investigator)
- NCT03067181 (Principal Investigator)
- NCT03914625 (Principal Investigator)
- NCT03007147 (Principal Investigator)
- NCT02402244 (Principal Investigator)
- NCT03126916 (Principal Investigator)
- NCT04322318 (Principal Investigator)
- NCT04293562 (Principal Investigator)
- NCT00898755 (Principal Investigator)
- NCT00898365 (Principal Investigator)
- NCT02176967 (Principal Investigator)
- NCT00904241 (Principal Investigator)
- NCT03959085 (Principal Investigator)
- NCT00772200 (Principal Investigator)
Conditions:
David Malkin
Seen in:
- Ontario, Toronto, Hospital for Sick Children
Trials:
- NCT02402244 (Principal Investigator)
Conditions:
Donna L. Johnston
Seen in:
- Ontario, Ottawa, Children's Hospital of Eastern Ontario
Trials:
- NCT04759586 (Principal Investigator)
- NCT04576117 (Principal Investigator)
- NCT02724579 (Principal Investigator)
- NCT03067181 (Principal Investigator)
- NCT03914625 (Principal Investigator)
- NCT03007147 (Principal Investigator)
- NCT02402244 (Principal Investigator)
- NCT03126916 (Principal Investigator)
- NCT04322318 (Principal Investigator)
- NCT03817398 (Principal Investigator)
- NCT04726241 (Principal Investigator)
- NCT04293562 (Principal Investigator)
- NCT00898365 (Principal Investigator)
- NCT02176967 (Principal Investigator)
- NCT00904241 (Principal Investigator)
- NCT04994132 (Principal Investigator)
- NCT03959085 (Principal Investigator)
- NCT00772200 (Principal Investigator)
- NCT03223753 (Principal Investigator)
- NCT00082745 (Principal Investigator)
Conditions:
Dr Cindy Boulanger-Gobeil
Seen in:
- Quebec, Québec City, Hotel-Dieu de Quebec
Trials:
- NCT03860883 (Principal Investigator)
Conditions:
- Cutaneous Melanoma, Stage II
Dr Frances Wright
Seen in:
- Ontario, Toronto, Sunnybrook Health Sciences Centre
Trials:
- NCT03860883 (Principal Investigator)
Conditions:
- Cutaneous Melanoma, Stage II
Dr. Carolyn Nessim
Seen in:
- Ontario, Ottawa, Ottawa Hospital Research Institute
Trials:
- NCT03860883 (Principal Investigator)
Conditions:
- Cutaneous Melanoma, Stage II
Dr. Mai-Kim Gervais
Seen in:
- Quebec, Montreal, Hopital Maisonneuve-Rosemont
Trials:
- NCT03860883 (Principal Investigator)
Conditions:
- Cutaneous Melanoma, Stage II
Dr. Renee Hanrahan
Seen in:
- Ontario, Barrie, Royal Victoria Regional Health Centre
Trials:
- NCT03860883 (Principal Investigator)
Conditions:
- Cutaneous Melanoma, Stage II
Dr. Valerie Francescutti
Seen in:
- Ontario, Hamilton, Hamilton Health Sciences Centre
Trials:
- NCT03860883 (Principal Investigator)
Conditions:
- Cutaneous Melanoma, Stage II
Josee Brossard
Seen in:
- Quebec, Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
Trials:
- NCT04576117 (Principal Investigator)
- NCT03871257 (Principal Investigator)
- NCT04166409 (Principal Investigator)
- NCT03794349 (Principal Investigator)
- NCT03067181 (Principal Investigator)
- NCT03914625 (Principal Investigator)
- NCT03007147 (Principal Investigator)
- NCT02402244 (Principal Investigator)
- NCT05304585 (Principal Investigator)
- NCT05235165 (Principal Investigator)
- NCT04322318 (Principal Investigator)
- NCT04293562 (Principal Investigator)
- NCT05675410 (Principal Investigator)
- NCT02176967 (Principal Investigator)
- NCT04994132 (Principal Investigator)
- NCT03959085 (Principal Investigator)
Conditions:
Kathleen Felton
Seen in:
- Saskatchewan, Saskatoon, Jim Pattison Children's Hospital
Trials:
- NCT02724579 (Principal Investigator)
- NCT03533582 (Principal Investigator)
- NCT03914625 (Principal Investigator)
- NCT03007147 (Principal Investigator)
- NCT02402244 (Principal Investigator)
- NCT04293562 (Principal Investigator)
- NCT02176967 (Principal Investigator)
- NCT03959085 (Principal Investigator)
Conditions:
Laura Wheaton
Seen in:
- Ontario, Kingston, Kingston Health Sciences Centre
Trials:
- NCT02724579 (Principal Investigator)
- NCT03794349 (Principal Investigator)
- NCT03533582 (Principal Investigator)
- NCT03067181 (Principal Investigator)
- NCT03914625 (Principal Investigator)
- NCT03007147 (Principal Investigator)
- NCT02402244 (Principal Investigator)
- NCT03126916 (Principal Investigator)
- NCT04293562 (Principal Investigator)
- NCT02176967 (Principal Investigator)
- NCT04994132 (Principal Investigator)
- NCT03959085 (Principal Investigator)
- NCT03223753 (Principal Investigator)
Conditions:
Lisa A. Goodyear
Seen in:
- Newfoundland and Labrador, Saint John's, Janeway Child Health Centre
Trials:
- NCT04759586 (Principal Investigator)
- NCT02724579 (Principal Investigator)
- NCT04166409 (Principal Investigator)
- NCT03794349 (Principal Investigator)
- NCT03067181 (Principal Investigator)
- NCT03914625 (Principal Investigator)
- NCT02402244 (Principal Investigator)
- NCT03126916 (Principal Investigator)
- NCT04322318 (Principal Investigator)
- NCT00898365 (Principal Investigator)
- NCT02176967 (Principal Investigator)
- NCT00904241 (Principal Investigator)
- NCT03959085 (Principal Investigator)
- NCT03223753 (Principal Investigator)
Conditions:
Marcus Butler, MD
Seen in:
- Ontario, Toronto, Princess Margaret Cancer Centre
Trials:
- NCT04044859 (Principal Investigator)
Conditions:
Marcus O. Butler
Seen in:
- Ontario, Toronto, University Health Network-Princess Margaret Hospital
Trials:
- NCT05111574 (Principal Investigator)
Conditions:
Michael Smylie, M.D.
Seen in:
- Alberta, Edmonton, Cross Cancer Institute
Trials:
- NCT02700971 (Principal Investigator)
Conditions:
- Metastatic Melanoma
Monia Marzouki
Seen in:
- Quebec, Montreal, Centre Hospitalier Universitaire Sainte-Justine
Trials:
- NCT04759586 (Principal Investigator)
- NCT04576117 (Principal Investigator)
- NCT03155620 (Principal Investigator)
- NCT02724579 (Principal Investigator)
- NCT05071209 (Principal Investigator)
- NCT03871257 (Principal Investigator)
- NCT05286801 (Principal Investigator)
- NCT03794349 (Principal Investigator)
- NCT03533582 (Principal Investigator)
- NCT03067181 (Principal Investigator)
- NCT05099003 (Principal Investigator)
- NCT03007147 (Principal Investigator)
- NCT02402244 (Principal Investigator)
- NCT05359237 (Principal Investigator)
- NCT05304585 (Principal Investigator)
- NCT04684368 (Principal Investigator)
- NCT05235165 (Principal Investigator)
- NCT04322318 (Principal Investigator)
- NCT03817398 (Principal Investigator)
- NCT04726241 (Principal Investigator)
- NCT04293562 (Principal Investigator)
- NCT05675410 (Principal Investigator)
- NCT04994132 (Principal Investigator)
Conditions:
Nathalie Daaboul, MD
Seen in:
- Quebec, Longueuil, CISSS de la Montérégie-Centre- Hôpital Charles-Le Moyne
Trials:
- NCT05303493 (Principal Investigator)
Conditions:
Nicolas Marcoux, MD
Seen in:
- Quebec, Québec, CHU de Québec, Centre intégré en cancérologie (CIC), Hôpital de L'Enfant-Jésus
Trials:
- NCT04951583 (Principal Investigator)
Conditions:
- Non Small Cell Lung Cancer Metastatic;
- Advanced Melanoma
Rossanna Pezo, MD
Seen in:
- Ontario, Toronto, Sunnybrook Health Sciences Centre/Sunnybrook Research Institute
Trials:
- NCT04951583 (Principal Investigator)
Conditions:
- Non Small Cell Lung Cancer Metastatic;
- Advanced Melanoma
Samuel Saibil
Seen in:
- Ontario, Toronto, University Health Network- Princess Margaret Cancer Centre
- Other, Toronto, University Health Network, Princess Margaret Hospital
Trials:
- NCT05571839 (Principal Investigator)
- NCT06377111 (Principal Investigator)
Conditions:
Sarah J. McKillop
Seen in:
- Alberta, Edmonton, University of Alberta Hospital
Trials:
- NCT04759586 (Principal Investigator)
- NCT04576117 (Principal Investigator)
- NCT03533582 (Principal Investigator)
- NCT03067181 (Principal Investigator)
- NCT03914625 (Principal Investigator)
- NCT03007147 (Principal Investigator)
- NCT02402244 (Principal Investigator)
- NCT05304585 (Principal Investigator)
- NCT04684368 (Principal Investigator)
- NCT05235165 (Principal Investigator)
- NCT04322318 (Principal Investigator)
- NCT03817398 (Principal Investigator)
- NCT04726241 (Principal Investigator)
- NCT04293562 (Principal Investigator)
- NCT00898365 (Principal Investigator)
- NCT05675410 (Principal Investigator)
- NCT02176967 (Principal Investigator)
- NCT00904241 (Principal Investigator)
- NCT04994132 (Principal Investigator)
- NCT03959085 (Principal Investigator)
- NCT04089358 (Principal Investigator)
- NCT00082745 (Principal Investigator)
Conditions:
Sharon B. Abish
Seen in:
- Quebec, Montreal, The Montreal Children's Hospital of the MUHC
Trials:
- NCT02724579 (Principal Investigator)
- NCT01790152 (Principal Investigator)
- NCT03794349 (Principal Investigator)
- NCT03533582 (Principal Investigator)
- NCT02402244 (Principal Investigator)
- NCT04293562 (Principal Investigator)
- NCT02176967 (Principal Investigator)
- NCT00904241 (Principal Investigator)
- NCT03959085 (Principal Investigator)
Conditions:

Clinical Trials on Melanoma

H. Lee Moffitt Cancer Center and Research Institute
Turnstone Biologics, Corp.

Recruiting

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Metastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous Melanoma

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditions

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma

Recurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA Melanoma

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); University of Virginia

Completed

Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma

Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin Melanoma

United States
MelanomaPRO, Russia

Recruiting

Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice (ISABELLA)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, Ocular

Russian Federation
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Stage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC Melanoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); National Comprehensive Cancer Network

Terminated

Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery

Recurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA Melanoma

United States
Emory University
Genentech, Inc.

Active, not recruiting

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IV

United States
Biocad

Recruiting

A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma (OCTAVA)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma Advanced

India, Russian Federation, Belarus

Medical specialists from Canada tagged as investigators in clinical trials studying Melanoma

Clinical Trials on Melanoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations